BURLINGTON, Mass., Oct. 6, 2017 /PRNewswire/ -- Decision Resources Group finds that the pancreatic cancer market will grow from $1.3 billion in 2016 to $3.7 billion in 2026. This growth will be fueled by the increased penetration of existing branded chemotherapy agents, and the approval of novel premium-priced targeted agents for the treatment of metastatic disease.

Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group)

Other key findings from the Disease Landscape & Forecast report entitled Pancreatic Cancer:

  • Increased market penetration of current therapies: DRG anticipates an increase in uptake of Ipsen/Shire's Onivyde in Europe and the United States, and a launch in Japan in 2019 is expected. Adoption of Celgene's Abraxane (with gemcitabine) as the standard of care for locally advanced and metastatic disease is expected; we also anticipate label expansion in the adjuvant setting for resectable patients, and further increase in uptake as a backbone in upcoming combination therapies. Keytruda, although approved for only a small patient subpopulation, will be a significant contributor in second-line pancreatic cancer market.
  • Emerging therapies for metastatic pancreatic cancer: The first-line setting is the most dynamic treatment setting in pancreatic cancer, and we expect the launch of three additional novel targeted agents in this space by 2026 – PEGPH20 (Halozyme's pegylated hyaluronidase), napabucasin (Dainippon Sumitomo's STAT3 inhibitor), and Lynparza (AstraZeneca's PARP inhibitor). DRG expects the launch of the immunotherapeutic agent – PEG-ilodecakin (ARMO Biosciences' recombinant pegylated interleukin-10) for the second-line treatment of pancreatic cancer.
  • The pancreatic neuroendocrine tumors market: The recent approval of Ipsen/Teijin's Somatuline Autogel in Japan will increase the value of the overall pancreatic cancer therapy market. However, the small PNETs market will decline in value, and its share of the overall pancreatic cancer market will depreciate from 13% in 2016 to 4% in 2026, primarily due to the generic erosion of the major players – Ipsen/Teijin's Somatuline Autogel (lanreotide extended-release), Novartis's Afintior (everolimus), and Pfizer's Sutent (sunitinib), and the lack of new product launches in the forecast period.
  • Declining market value after 2024: The already-highly genericized pancreatic cancer market will see a decline in growth after 2024 due to the generic erosion of most important players; this value decline is unlikely to be offset by the emerging therapies.

Comments from Decision Resources Group Analyst Anamika Ghosh, PhD:

  • "Approval of PEGPH20 is highly anticipated. It will be the first-ever targeted therapy to receive approval for the treatment of first-line metastatic pancreatic cancer. It is set to be the forerunner of biomarker-based stratification in pancreatic cancer as the therapy has shown impressive clinical results in patients with high levels of hyaluronan."
  • "Lynparza is expected to pave a new path in medical practice for pancreatic by introducing the concept of maintenance therapy to pancreatic cancer. Although the therapy will benefit only a very small patient subpopulation – only patients with gBRCA mutation that respond to platinum-based first-line therapy – this will still be a huge leap in the treatment of pancreatic cancer."

Additional Resources:

  • Anamika Ghosh has written a blog on the subject, which can be found here.

For more information on purchasing this report, please visit our website.

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Stephanie Cooper
212-414-7570
scooper@dresources.com

SOURCE Decision Resources Group

The Launch of First-in-Class Biologic Therapies Will Drive Significant Growth Within the Osteoarthritic Pain Market Through 2026

View Now